Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QSC303294
- Development stage
- Phase 1
- Lead developer
- Bial
- Administration
- Oral
01
Overview
QSC303294 is an investigational drug candidate being developed by BIAL. It is currently in Phase I clinical development, with a completed study (ISRCTN16910437) conducted in the United Kingdom to evaluate the safety, tolerability, and pharmacokinetics of different formulations in healthy volunteers. Due to the early-stage nature of the program, the sponsor has deferred publication of the full trial details, meaning the specific therapeutic indication, molecular target, and chemical structure of the compound remain proprietary and are not yet publicly available.
Beyond the preview
Go deeper on QSC303294.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QSC303294.